| Code | CSB-RA857869MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Vixarelimab, targeting the Oncostatin M Receptor (OSMR). OSMR is a type I cytokine receptor that forms heterodimeric complexes with gp130 to mediate signaling by oncostatin M (OSM), a member of the interleukin-6 cytokine family. This receptor plays critical roles in inflammatory responses, tissue remodeling, and hematopoiesis. OSMR signaling has been implicated in various pathological conditions, including inflammatory bowel disease, fibrotic disorders, and certain cancers, where OSM-OSMR axis activation contributes to chronic inflammation, extracellular matrix deposition, and tumor progression.
Vixarelimab is a therapeutic antibody designed to block OSMR signaling, currently under investigation for treatment of inflammatory and fibrotic diseases. This biosimilar provides researchers with a valuable tool for investigating OSMR-mediated pathways, studying the role of oncostatin M in disease pathogenesis, and exploring therapeutic interventions targeting this cytokine receptor system. It enables detailed examination of OSMR function in cellular and molecular biology research contexts.
There are currently no reviews for this product.